MEGACE ES Rx
Generic Name and Formulations:
Megestrol acetate 125mg/mL; oral susp; lemon-lime flavor.
Par Pharmaceutical, Inc.
Indications for MEGACE ES:
Anorexia, cachexia, or unexplained significant weight loss in patients diagnosed with AIDS.
Limitations Of use:
Should only be instituted after treatable causes of weight loss are sought and addressed. Not for prophylactic use to avoid weight loss.
625mg/5mL per day.
Known or suspected pregnancy (Cat.X).
Do not substitute with other megestrol suspensions (not interchangeable). History of thromboembolic disease. Monitor for signs/symptoms of adrenal insufficiency; consider empiric therapy if occurs. Diabetes. Renal impairment. Elderly. Avoid in women of childbearing potential. Nursing mothers: not recommended.
May increase insulin requirements. Decreases indinavir levels.
Nausea, diarrhea, impotence, rash, flatulence, hypertension, asthenia; rare: adrenal insufficiency, breakthrough bleeding.
Concentrated susp (125mg/mL)—5oz
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics